MMIT Reality Check on Hereditary Angioedema (Mar 2020)

According to our recent payer coverage analysis for hereditary angioedema treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for hereditary angioedema treatments shows that under the pharmacy benefit, about 67% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: The FDA will review BioCryst Pharmaceuticals, Inc.’s application for oral, once daily berotralstat for the prevention of swelling attacks in patients with hereditary angioedema, with a decision expected by early December 2020.

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-reality-check-hemophilia.jpg
October 15

MMIT Reality Check on Hemophilia A (Factor VIII) (Oct 2021)

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/10/wordpress-featured-image-reality-check-diffuse-large-b-cell-lymphoma.jpg
October 8

MMIT Reality Check on Diffuse Large B-Cell Lymphoma (Oct 2021)

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/WordPress-Featured-Image_Pulse-Check_MS.jpg
October 1

MMIT Reality Check on Multiple Sclerosis (Oct 2021)

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today